
CLAIMS:

We claim:

1. An orally administrable pharmaceutical formulation comprising
(a) compound of Formula (I)



(I)

wherein

R_1 is halo, cyano, optionally substituted lower alkyl, or optionally substituted lower alkoxyl; and

R_2 is optionally substituted aryl, or optionally substituted heterocyclyl;

or a prodrug, or pharmaceutically acceptable salt thereof;

(b) at least one diluent or filler;

(c) optionally at least one disintegrant;

(d) optionally at least one binder; and

(e) optionally at least one lubricant;

wherein

the compound of formula (I) is present in an amount within the range of from about 1% to about 80% by weight;

the diluent or filler is present in an amount within the range of from about 10% to about 95% by weight;

the disintegrant, if present, is present in an amount within the range of from about 0.1% to about 20% by weight;

the binder, if present, is present in an amount within the range of from about 0.1% to about 20% by weight; and


the lubricant, if present, is present in an amount within the range of from about 0.1% to about 5% by weight, all of the above % by weight being based on the weight of the formulation.

2. The pharmaceutical composition of claim 1 wherein

R_1 is a halogen atom, or a lower alkyl group; and

R_2 is phenyl optionally substituted by 1 to 3 substituents selected from the group consisting of a halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethylenedioxy group, a mono-or di-lower alkylamino group, a carbamoyl group, and a mono-or di-lower alkylcarbamoyl group.

3. The pharmaceutical composition of claim 1 wherein the compound of Formula (I) is the compound of formula (I-S):



(I-S);

or a prodrug, or pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition of claim 3, wherein the compound is present in an amount of about 25 mg to about 600 mg.

5. The pharmaceutical composition of claim 3, wherein the compound is present in an amount of about 50 mg to about 300 mg.

6. The pharmaceutical composition of claim 3, wherein the compound is present in an amount of about 100 mg.

7. The pharmaceutical composition of claim 3, wherein the compound is present in an amount of about 300 mg.

8. The pharmaceutical composition of claim 1, wherein the compound is 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) hemihydrate.

9. The pharmaceutical composition of claim 1, wherein the formulation is a tablet.


10. A method for treating a sodium-dependent glucose transporter mediated disorder, said method comprising administering to a patient in need thereof, the pharmaceutical composition of claim 3.

11. The method of claim 10 wherein the compound is administered at a dose of from about 50 mg to about 300 mg once daily.

12. The method of claim 10 wherein the compound is administered at a dose of about 100 mg per day.

13. The method of claim 10 wherein the compound is administered at a dose of about 300 mg per day.

14. An orally administrable pharmaceutical formulation comprising
(a) a compound of Formula (I-S)



(I-S),

or a prodrug or pharmaceutically acceptable salt thereof present in an amount within the range of from about 40% to about 60% by weight;

(b) at least one diluent or filler present in an amount within the range of from about 30% to about 50% by weight ;

(c) at least one disintegrant in an amount within the range of from about 3% to about 10% by weight;

(d) at least one binder present in an amount within the range of from about 0.5% to about 5% by weight; and

(e) at least one lubricant present in an amount within the range of from about 0.5% to about 2% by weight;

wherein the % by weight is based on the weight of the formulation.

15. The pharmaceutical composition of claim 14, wherein the compound is 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene) hemihydrate.


16. The pharmaceutical composition of claim 14, wherein the formulation is a tablet.

17. The pharmaceutical composition of claim 15, wherein the formulation is a tablet.

CLAIMS

1. A method for treating a sodium-dependent glucose transporter mediated disorder, said method comprising administering to a patient in need thereof, an orally administrable pharmaceutical formulation comprising

(a) compound of Formula (I)



(I)

(b) at least one diluent or filler;

(c) optionally at least one disintegrant;

(d) optionally at least one binder; and

(e) optionally at least one lubricant;

wherein

the compound of formula (I) is present in an amount within the range of from about 1% to about 80% by weight;

the diluent or filler is present in an amount within the range of from about 10% to about 95% by weight;

the disintegrant, if present, is present in an amount within the range of from about 0.1% to about 20% by weight;

the binder, if present, is present in an amount within the range of from about 0.1% to about 20% by weight; and

the lubricant, if present, is present in an amount within the range of from about 0.1% to about 5% by weight, all of the above % by weight being based on the weight of the formulation.